Taysha Gene Therapies (TSHA) Shares Outstanding (2019 - 2026)

Taysha Gene Therapies has disclosed Shares Outstanding across 8 years of filings, most recently posting $287.3 million for Q1 2026.

• Shares Outstanding for Q1 2026 came in at $287.3 million, up 40.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $287.3 million (up 40.1% YoY), and the FY2025 annual result was $285.1 million, up 39.09% from the prior year.
• Shares Outstanding came in at $287.3 million for Q1 2026 at Taysha Gene Therapies, up from $285.1 million in the prior quarter.
• In the past five years, Shares Outstanding ranged from a high of $287.3 million in Q1 2026 to a low of $38.5 million in Q1 2022.
• The 5-year median for Shares Outstanding is $187.0 million (2024), against an average of $165.2 million.
• Across the five-year window, Shares Outstanding gained 1.89% in 2022 and surged 354.05% in 2023, its largest moves.
• Taysha Gene Therapies' Shares Outstanding stood at $63.2 million in 2022, then jumped by 195.79% to $187.0 million in 2023, then grew by 9.62% to $204.9 million in 2024, then soared by 39.09% to $285.1 million in 2025, then gained by 0.78% to $287.3 million in 2026.
• The last three Shares Outstanding figures came in at $287.3 million (Q1 2026), $285.1 million (Q4 2025), and $273.9 million (Q3 2025), per Business Quant data.